1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Concord Drugs Limited

Concord Drugs Limited

CONCORD.BO
Concord Drugs LimitedIN flagBombay Stock Exchange
82.50
INR
+2.40
- -
916.18MMarket Cap
Concord Drugs Limited
CONCORD.BO
(Bombay Stock Exchange)

Recent

price

82.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
47.1
55.25
69.97
79.36
65.88
61.15
58.71
58.73
67.43
55.91
44.92
45.24
45.9
Revenue per Share
0.47
0.96
2.41
0.22
0.41
0.52
0.38
3.75
1.82
1.06
0.47
0.34
0.51
Basic EPS, GAAP
- -
0.89
3.39
0.91
8.75
1.52
2.84
- -
0.89
1.79
0.79
3.72
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
17.82
20.23
20.45
20.04
20.56
19.87
23.62
25.45
25.46
24.82
25.11
- -
Book Value per Share
- -
18.38
20.8
26.22
24.58
29.45
26.86
30.61
32.43
34.04
33.82
34.11
- -
Tangible Book Value per Share
7
7
7
7
8
8
9
9
9
9
10
10
11
Basic Weighted Avg Shares
340
400
507
575
518
481
513
514
590
521
449
452
512
Sales/Revenue/Turnover
6.51
9.41
11.02
5.19
4.29
5.18
3.66
3.89
15.54
5.84
5.65
6.13
5.41
Operating Margin (%)
11
36
29
26
24
17
15
14
18
16
16
14
14
Depreciation Expense
3
7
17
2
3
4
3
33
16
10
5
3
6
Net Income, GAAP
20.93
33.63
41
75.35
49.25
7.44
28.08
23.54
29.08
21.09
24.9
51.37
27.8
Effective Tax Rate (%)
1
1.74
3.45
0.28
0.63
0.85
0.64
6.39
2.7
1.89
1.05
0.74
1.1
Profit Margin (%)
- -
75
22
9
113
137
146
198
182
218
165
146
- -
Working Capital
- -
126
122
62
34
7
9
38
17
19
6
13
- -
LT Debt
- -
133
151
190
193
232
235
268
284
317
338
341
- -
Total Equity
- -
14.45
9.18
2.04
3.3
6.91
4.06
4.15
15.15
5.08
3.79
2.57
- -
Return on Invested Capital (%)
- -
14.43
9.41
2.33
4.12
6.72
5.17
14.2
7.7
5.92
4.52
3.01
-3.73
Return on Capital (%)
- -
10.79
12.69
1.08
2.12
2.55
1.96
17.26
7.43
4.29
1.95
1.35
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
161
- -
LT Borrowings
- -
10
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
10
- -
Market Capitalization
419
662
921

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
460
- -
Cash, Cash Equivalents & STI
- -
5
- -
Accounts Receivable, Net
- -
172
- -
Inventories
- -
257
- -
Total Current Liabilities
- -
297
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
161
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.15%
7.85%
0.87%
Free Cash Flow
478,041.89%
955,848.91%
369.77%
Net Income, GAAP
89.87%
145.82%
-28.82%
Sales/Revenue/Turnover
1.99%
-1.97%
0.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
75
128
156
449
2025
117
124
108
104
452
2026
136
103
170
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.53
0.6
-0.24
- -
0.47
2025
0.03
0.04
0.23
- -
0.34
2026
0.12
0.19
0.16
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Sunrest Lifescience Ltd. (SUNREST.NS)
Heartseed, Inc. (219A.T)
Tyche Industries Limited (TYCHE.BO)
Desh Rakshak Aushdhalaya Ltd. (DESHRAK.BO)
PharmaRoth Labs, Inc. (ROTH)
Medicamen Organics Ltd. (MEDIORG.NS)
Business
Concord Drugs Limited (CONCORD.BO), a public limited company founded in 1995 and headquartered in Hyderabad, India, manufactures and sells pharmaceutical formulations, specializing in finished dosage forms and contract manufacturing services through WHO-GMP and cGMP-certified facilities located in Hyderabad, Telangana, and Roorkee, Uttarakhand; its core products encompass ready-to-fill pellets and multiple unit pellet systems (MUPS) with sustained release, modified release, enteric, delayed, and immediate release technologies; tissue bio-adhesives; small volume parenteral injectables; oral solid dosages including tablets and capsules; liquid orals such as syrups and suspensions; dry syrup powders; and additional offerings like hand sanitizers, serving domestic markets and select international registrations with emphasis on generics, branded formulations, and innovative drug delivery for prescription and over-the-counter applications. The company operates primarily in the Indian pharmaceutical sector, providing end-to-end solutions from research and development to commercial contract manufacturing for partners requiring high-quality, regulatory-compliant products. In recent developments, Concord Drugs approved the acquisition of up to 100% stake in Proton Remedies Private Limited in September 2022 for INR 14.2 million to expand its portfolio and capabilities; in November 2025, it closed a preferential funding round raising INR 133.6 million through equity shares and convertible warrants issued to promoters and investors at INR 36.30 per unit, bolstering financial resources amid quarterly net sales of INR 10.07 crore for September 2025; ongoing expansions include a dry syrup section started in 2021 and oral solid dosage production initiated in 2018.